Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582918 · ClinicalTrials.gov registry record · NA
Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 2,871
- Enrollment target
NCT02582918 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 2,871 participants.
The verdict
NCT02582918, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,871 participants
- Enrollment target
Study Summary
Project 5 of the Texas HCC Consortium (THCCC) is a comparative effectiveness pragmatic randomized control trial (RCT) of outreach strategies to increase hepatocellular cancer (HCC) surveillance process completion among a socioeconomically and racially diverse cohort of Texans with cirrhosis. Through this project the investigators will implement and evaluate system-level mailed outreach interventions to identity at-risk patients with cirrhosis, promote HCC surveillance, and ensure timely follow-up of tests at UT Southwestern (UTSW) Medical Center, Parkland Health and Hospital System (PHHS), and the Houston Veterans Affairs (VA) Medical Center. The study population will include adult patients with documented or unrecognized cirrhosis and at least one outpatient clinic visit in year prior to randomization. Patients will be identified using an EMR-enabled case identification algorithm. The investigators will randomize 3000 patients (1500 per arm) identified by this algorithm to: usual care, with opportunistic visit-based HCC surveillance (Group 1); or, mailed HCC surveillance outreach with patient education and patient navigation services (Group 2).
Interventions
- BEHAVIORAL Outreach with patient education and patient navigation services
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,871 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02582918
The ClinicalTrials.gov registry entry for NCT02582918 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,871 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Outreach with patient education and patient navigation services is the first listed.
NCT02582918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02582918 about?
NCT02582918 is a clinical study titled "Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5". Project 5 of the Texas HCC Consortium (THCCC) is a comparative effectiveness pragmatic randomized control trial (RCT) of outreach strategies to increase hepatocellular cancer (HCC) surveillance process completion among a socioeconomically and racially diverse cohort of Texans with cirrhosis. Through...
What is the current status of trial NCT02582918?
This trial is currently completed. It is a NA study. The enrollment target is 2,871 participants. The study started on 2018-03-26. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT02582918?
The interventions under investigation include: Outreach with patient education and patient navigation services (BEHAVIORAL).
Who is sponsoring clinical trial NCT02582918?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.